The serum 1,5-anhydro-d-glucitol (1,5-AG) level rapidly decreases concomitantly with urinary glucose excretion in hyperglycemia. 1,5-AG is a sensitive clinical marker of short-term glycemic control, postprandial hyperglycemia and glucose fluctuation. Increasing evidence about the relationship between cardiovascular disease (CVD) and glucose fluctuations have been published. In this review, we summarize the possibilities and limitations of 1,5-AG as a marker of CVD. Research showed that 1,5-AG level is associated with prevalence of CVD and is also a predictive value for cardiovascular (CV) events. Especially in a high risk population, the predictive value of 1,5-AG for CV events becomes more effective. Besides, 1,5-AG is an effective glycometabolic marker that complements HbA1c in terms of glucose fluctuation. Appropriate use of 1,5-AG might lead to improved prognosis for patients or decrease medical financial burden of the population through early detection of glucose disorder and quality glucose control.
Introduction
Type 2 diabetes mellitus (DM) extremely impairs the prognosis of patients with cardiovascular disease (CVD) (1) . Currently, because of the well-established relationships between micro-vascular disease and hemoglobin A1c (HbA1c), the American Diabetes Association (ADA) recommends the evaluation of HbA1c as a criterion for diagnosing DM (2) . The United Kingdom Prospective Diabetes Study (UKPDS) and the Diabetes Control and Complications Trial (DCCT) have shown that long-term favorable glycemic control improves the complications of DM (3, 4) . However, in patients with advanced DM, HbA1c guided intensive glucose control does not always reduce macro-vascular complications, and in some cases increases the risk of death (5) (6) (7) . To improve the patient's prognosis, early diagnosis and early intervention for glycemic abnormalities are essential (4) . Increasing evidence has reported that postprandial hyperglycemia and glucose level fluctuation impairs mortality rate and promotes CVD progression (8) (9) (10) (11) (12) (13) (14) . Feasible and sensitive clinical markers to detect glucose fluctuations are needed.
1,5-anhydro-d-glucitol (1,5-AG)
1,5-AG is a monosaccharide originating primarily from dietary sources that is found in constant concentrations in the blood in normal glycemic status (15) . 1,5-AG is a naturally occurring 1-deoxy form of glucose ( Figure   1 ) and was discovered in a milkwort plant, Polygala senega in 1888. Further investigation was repeated and became commercially available in Japan from 1991 (Table 1) . Approximately 500 to 1,000 mg 1,5-AG exists in the human body mainly in its free form (15) . 1,5-AG is adjusted by urinary excretion in the kidneys. Most 1,5-AG, which is filtered in glomerulus is reabsorbed at a specific fructose-mannose active transporter in the renal tubule (15, 16) (Figure 2A ). The reabsorption is competitively inhibited by glucose. Therefore, the serum 1,5-AG level rapidly decreases when the serum glucose level exceeds the threshold of urine glucose excretion (160-180 mg/dL) and is an important and feasible clinical marker of short-term glycemic status ( Figure  2B ) (17, 18) . Therefore, low 1,5-AG is associated with postprandial hyperglycemia or poor glycemic control status. Yamanouchi reported distribution of 1,5-AG levels in Japanese healthy subjects (Male: 26.6 ± 7.2 μg/ mL, Female: 21.5 ± 6.0 μg/mL, Total: 24.6 ± 7.2 μg/mL) (19) . There is no significant statistical difference between lower limits of healthy males and females (Male: 14.2 μg/mL, Female: 13.5 μg/mL). Therefore, as the normal lower limit of 1,5-AG levels, a cut-off value of 14.0 μg/ mL calculated by all healthy subjects is recommended (19) . The mean 1,5-AG value of patients with DM was 7.3 ± 7.1 μg/mL and was significantly lower than that of healthy subjects ( Figure 3 ) (19) .
Unlike HbA1c, although the 1,5-AG value is not affected by red blood cell life span, several clinical conditions should be considered in interpretation of 1,5-AG values ( Table 2 ). Recently the use of sodiumglucose cotransporter 2 inhibitor (SGLT2i) has been rapidly increasing. Although SGLT2i improves glycemic control, serum 1,5-AG decreases. The reabsorption of 1,5-AG occurs predominantly via a SGLT4 and the effect of SGLT2i for 1,5-AG reabsorption is indirect (20) . The amount of glycosuria caused by SGLT2i is about 60-80 g/day. Serum 1,5-AG level will be reduced to 0-1 μg/ mL in a week, when a large amount of glycosuria (above 50 g/day) appears. If SGLT2i therapy causes substantial glycosuria, the serum 1,5-AG level will generally decrease to near 1 μg/mL in a week after administration. If serum 1,5-AG levels increase during administration, it could show decreasing effectiveness of SGLT2i.
Postprandial hyperglycemia and glucose fluctuation
It is well known that postprandial hyperglycemia is associated with cardiovascular (CV) events (14) . Recently, there has been increasing evidence that fluctuations in glucose levels leads to endothelial dysfunction and increases the risk of CV events and the progression of (84) www.globalhealthmedicine.com Table 1 (85) CAD showed significantly lower 1,5-AG values than those without CAD (25, 28) . Fujiwara presented that serum 1,5-AG was significantly lower in patients with CAD (16.6 ± 8.50 vs. 21.1 ± 7.97 μg/mL, p < 0.001) (28) . Ikeda showed that patients with CAD presented significantly lower 1,5-AG and higher HbA1c values than patients without CAD (11.6 vs. 17.6 μg/mL, p < 0.001, and 6.0% vs. 5.7%, p < 0.001, respectively) (25) . In addition, 1,5-AG values have a correlation with severity of CAD assessed by SYNTAX score (ρ = -0.27, p < 0.001) (25) . Even in patents without DM, serum 1,5-AG values can be a help to detect the prevalence of CAD, and the correlation is superior to HbA1c (26, 28) . Watanabe evaluated carotid arteries of 72 patients without DM and CVD by high-resolution ultrasonography. They reported that a higher pulsatility index of carotid arteries is associated with lower 1,5-AG values, but intima media thickness was not correlated with 1,5-AG values (27) . They suggested that 1,5-AG is associated with stiffness but not with morphological changes of carotid arteries (27) . Shiga demonstrated that a low serum 1,5-AG value (1,5-AG < 14 μg/mL) is a marker for acute ischemic stroke or transient ischemic attacks in patients with wellcontrolled DM (HbA1c < 7%) (29) .
. History of 1,5-Anhydro-d-glucitol

Prediction of cardiovascular events
There is a certain consensus that 1,5-AG can be used to predict cardiovascular events in patients with DM. The evidence was reported that a lower serum 1,5-AG value is associated with cardiovascular events, mainly from Japan (30) (31) (32) (33) (34) (35) (Table 3) .
Watanabe showed that the measurement of serum 1,5-AG is useful to detect high risk men for CVD, regardless of the presence or absence of diabetes (34) . This report is a relatively long-term (11 years) population-based cohort study. The usefulness of 1,5-AG was limited. Selvin demonstrated the data from Atherosclerosis Risk in a Communities (ARIC) study. Compared with persons with 1,5-AG ≥ 6.0 μg/mL and no history of DM, persons with DM and 1,5-AG < 6.0 μg/mL showed an increased risk of cardiovascular events (35) . However, the predictive value of CVD or CV events was inadequate in the population without diagnosis of DM (35) . The study subjects of these two cohort studies were low risk for CVD or a healthy population (34, 35) . In such a low risk population, the effectiveness of 1,5-AG for prediction of CV events might not have been fully evaluated. On the other hand, in high risk populations, the predictive value of 1,5-AG for CV events is excellent. Low serum 1,5-AG values are significantly associated with cardiac mortality or adverse clinical events in patients with CAD (31-33). Fujiwara evaluated 141 patients after percutaneous coronary intervention (PCI) with followup coronary angiography (CAG). Median 1,5-AG values were significantly lower in patients with coronary revascularization (13.4 vs. 18.7 μg/mL, p < 0.01, p = atherosclerosis (21, 22) . Glucose fluctuations have a bad effect on coronary plaque vulnerability and progression in patients with CAD (10-13). These findings may explain the increased CV mortality rate during intensive glycemic therapy. Most evidence about glucose fluctuation and CV events or coronary plaques are based on continuous glucose monitoring (CGM) and oral glucose tolerance tests (OGTT) (10-14). 1,5-AG can be used to differentiate patients with glucose fluctuation despite having a similar HbA1c (23) .
As a reduced 1,5-AG value strongly correlates with glucose excursions, it is also associated with postprandial hyperglycemia (17, 18) . Furthermore, 1,5-AG values have been correlated with the mean amplitude of glycemic excursions (MAGE) and other parameters of CGM (23, 24) . Therefore, 1,5-AG has potential to be a marker for CVD and a predictor of CV events.
Relationship with CVD and events
Prevalence of coronary artery disease, carotid artery disease and acute ischemic stroke/transient ischemic attack
Several previous reports demonstrated that 1,5-AG is associated with prevalence of coronary artery disease (CAD) and carotid artery disease (25) (26) (27) (28) . Patients with www.globalhealthmedicine.com (86) 0.005) (31) . Takahashi showed that a low 1,5-AG value was associated with adverse clinical events after first time elective PCI even in patients with well-controlled DM (HbA1c < 7.0%) (32) . Ouchi presented that low 1,5-AG levels predict long-term cardiac mortality in patients with acute coronary syndrome with HbA1c levels < 7.0%. The 1,5-AG value of the cardiac death group was significantly lower than that of the survivor group (12.3 ± 5.3 vs. 19.2 ± 7.7 μg/mL, p < 0.01) (33) . Ikeda reported that in a high risk population, a low 1,5-AG value predicts major cardiac and cerebrovascular events (MACCE) even in non-DM patients without CAD. The study subjects were the patients who needed their first CAG. Therefore, these patients were potentially high risk even if CAG did not reveal CAD. The low 1,5-AG group (1,5-AG < 10.0 mg/mL) showed significantly higher risk of not only MACCE but also all causes of death (30) .
Conclusions
1,5-AG level is associated with prevalence of CV disease and has also predictive value for CV events. Especially in a high risk population, the predictive value for CV events of 1,5-AG becomes more effective. Measurement of serum 1,5-AG values is useful for not only evaluation of individual glucose control but also population risk assessment from a public health perspective. 1,5-AG is an effective glycometabolic marker that complements HbA1c in terms of glucose fluctuation. Appropriate use of 1,5-AG might lead to improved prognosis for patients or decreased medical financial burden of the population through early detection of glucose disorders and quality glucose control. control Low 1,5-AG value predicts cardiac and cerebrovascular events even in non-DM patients without CAD. Cut off value of 1,5-AG is 10μg/mL. Low 1,5-AG value is associated with adverse clinical events in patients with HbA1c < 7.0% after first time elective percutaneous coronary intervention Compared with persons with 1,5-AG ≥ 6.0μg/mL and no history of DM, persons with DM and 1,5-AG < 6.0μg/mL showed increased risk of cardiovascular events. Participants in the Atherosclerosis Risk in Communities (ARIC) study without CVD at baseline Low 1,5-AG value predicted long-term cardiac mortality in patients with acute coronary syndrome and HbA1c < 7.0%.
Low serum 1,5-AG value is a marker for acute ischemic stroke or transient ischemic attacks in patients with well-controlled DM.
The measurement of serum 1,5-AG value is useful to detect high risk men for CVD, regardless of the presence or absence of diabetes.
Lower 1,5-AG is a risk factor for adverse clinical events after percutaneous coronary intervention.
